Molecular mechanisms involved in the pathogenesis of septic shock

Archives of Medical Research

Volumn 35, Issue 6, 2004, Pages 465-479

  López Bojórquez, Lucia Nikolaia ^a,c   Dehesa, Alejandro Zentella ^a   Reyes Terán, Gustavo ^b  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^c UNIVERSIDAD AUTÓNOMA DE QUERÉTARO   (Mexico)

Author keywords

Inflammatory cytokines; NF B; Septic shock; SIRS; Toll receptors

Indexed keywords

ACETYLSALICYLIC ACID; ACUTE PHASE PROTEIN; ARGININE DERIVATIVE; BACTERIAL ANTIGEN; C REACTIVE PROTEIN; CANAVALIN; CHEMOKINE; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEFLUNOMIDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROCALCITONIN; PYRROLIDINE DITHIOCARBAMATE; SALAZOSULFAPYRIDINE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

APOPTOSIS; BLOOD FLOW; BLOOD VESSEL TONE; CALCIUM HOMEOSTASIS; CATABOLISM; CELL ACTIVATION; CELL POPULATION; CYTOKINE PRODUCTION; DEATH; DISEASE COURSE; DISSEMINATED INTRAVASCULAR CLOTTING; FEVER; GLUCONEOGENESIS; GLYCOLYSIS; GRAM NEGATIVE BACTERIUM; HUMAN; HYPERGLYCEMIA; HYPERLACTATEMIA; HYPOGLYCEMIA; IMMUNE RESPONSE; IMMUNE SYSTEM; INFLAMMATION; LIVER; MACROPHAGE ACTIVATION; MYOCARDIAL DISEASE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SEPTIC SHOCK; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TISSUE INJURY; VASCULAR ENDOTHELIUM;

EID: 22944443625     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2004.07.006     Document Type: Review

References (132)

1. Matzinger P. The danger model: a renewed sense of self. Science 2002;296(5566):301-305.
2. Levy MM FM, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G. International Sepsis Definitions Conference. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003;29(4):530-538.
3. Friedman GSE, Vincent JL. Has the mortality of septic shock changed with time. Crit Care Med 1998;26(12):2078-2086.
4. Sifuentes-Osornio JG-AM, Ponce de Leon-Garduno LA, Guerrero-Almeida ML. Trends for bacteremia and risk factors for death in a tertiary hospital in Mexico City. 1981-1992. Gac Med Mex 2001;137(3):191-202.
5. Zamora-Castorena S, Murgia-de-Sierra MT. Five year experience with neonatal sepsis in a pediatric center. Rev Invest Clin 1998;50(6):463-470.
6. Murphy K, Haudek SB, Thompson M, Giroir BP. Molecular biology of septic shock. New Horiz 1998;6(2):181-193.
7. Fantuzzi L, Puddu P, Varano B, Del Corno M, Belardelli F, Gessani S. IFN-alpha and IL-18 exert opposite regulatory effects on the IL-12 receptor expression and IL-12-induced IFN-gamma production in mouse macrophages: novel pathways in the regulation of the inflammatory response of macrophages. J Leukoc Biol 2000;68(5):707-714.
8. Tufano MA, Cipollaro de l'Ero G, Ianniello R, Galdiero M, Galdiero F. Protein A and other surface components of Staphylococcus aureus stimulate production of IL-1 alpha, IL-4, IL-6, TNF and IFN-gamma. Eur Cytokine Netw 1991;2(5):361-366.
9. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;383:787-793.
10. Nathan CF. Macrophage activation: some questions. Ann Inst Pasteur Immunol 1986;137C(3):345-351.
11. Aderem A. How to eat something bigger than your head. Cell 2002;110(1):5-8.
12. Abrahams VM, Cambridge G, Lydyard PM, Edwards JC. Induction of tumor necrosis factor alpha production by adhered human monocytes: a key role for Fcgamma receptor type IIIa in rheumatoid arthritis. Arthritis Rheum 2000;43(3):608-616.
13. Lebron F, Vassallo R, Puri V, Limper AH. Pneumocystis carinii cell wall beta-glucans initiate macrophage inflammatory responses through NF-kB activation. J Biol Chem 2003;25:25.
14. Fenton MJ, Golenbock DT. LPS-binding proteins and receptors. J Leukoc Biol 1998;64(1):25-32.
15. Iwahashi H, Takeshita A, Hanazawa S. Prostaglandin E2 stimulates AP-1-mediated CD14 expression in mouse macrophages via cyclic AMP-dependent protein kinase A. J Immunol 2000;164(10):5403-5408.
16. Hampton RY, Raetz CR. Macrophage catabolism of lipid A is regulated by endotoxin stimulation. J Biol Chem 1991;266(29):19499-19509.
17. Nathan C, Sporn M. Cytokines in context. J Cell Biol 1991;113(5):981-986.
18. Hamann L, Schumann RR, Flad HD, Brade L, Rietschel ET, Ulmer AJ. Binding of lipopolysaccharide (LPS) to CHO cells does not correlate with LPS-induced NF-kappaB activation. Eur J Immunol 2000;30(1):211-216.
19. Golenbock DT, Fenton MJ. Extolling the diversity of bacterial endotoxins. Nat Immunol 2001;2(4):286-268.
20. Guha M, O'Connell MA, Pawlinski R, Hollis A, McGovern P, Yan Stern D, Mackman N. Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor alpha expression by inducing Elk-1 phosphorylation and Egr-1 expression. Blood 2001;98(5):1429-1439.
21. Picard C, Puel A, Bonnet M, Ku CL, Bustamante J, Yang K, Soudais C, Dupuis S, Feinberg J, Fieschi C, Elbim C, Hitchcock R, Lammas D, Davies G, Al-Ghonaium A, Al-Rayes H, Al-Jumaah S, Al-Hajjar S, Al-Mohsen IZ, Frayha HH, Rucker R, Hawn TR, Aderem A, Tufenkeji H, Haraguchi S, Day NK, Good RA, Gougerot-Pocidalo MA, Ozinsky A, Casanova JL. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 2003;299(5615):2076-2079.
22. Zhang FX, Kirschning CJ, Mancinelli R, Xu XP, Jin Y, Faure E, Mantovani A, Rothe M, Muzio M, Arditi M. Bacterial lipopolysaccharide activates nuclear factor-kappaB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes. J Biol Chem 1999;274(12):7611- 7614.
23. Guo F, Wu S. IRAK-2 and PI 3-kinase synergistically activate NF-kappaB and AP-1. Inflammation 2000;24(4):305-316.
24. Takeuchi O, Akira S. Toll-like receptors; their physiological role and signal transduction system. Int Immunopharmacol 2001;1(4):625-635.
25. Akira S. Toll-like receptors: lessons from knockout mice. Biochem Soc Trans 2000;28(5):551-556.
26. Werts C, Tapping RI, Mathison JC, Chuang TH, Kravchenko V, Saint Girons I, Haake DA, Godowski PJ, Hayashi F, Ozinsky A, Underhill DM, Kirschning CJ, Wagner H, Aderem A, Tobias PS, Ulevitch RJ. Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism. Nat Immunol 2001;2(4):346-352.
27. Medzhitov R. CpG DNA: security code for host defense. Nat Immunol 2001;2(1):15-16.
28. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001;413(6857):732-738.
29. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S. A Toll-like receptor recognizes bacterial DNA. Nature 2000;408(6813):740-745.
30. Modlin RL. Activation of toll-like receptors by microbial lipoproteins: role in host defense. J Allergy Clin Immunol 2001;108(4 Suppl):S104-106.
31. Kengatharan KM, De Kimpe S, Robson C, Foster SJ, Thiemermann C. Mechanism of gram-positive shock: identification of peptidoglycan and lipoteichoic acid moieties essential in the induction of nitric oxide synthase, shock, and multiple organ failure. J Exp Med 1998;188(2):305-315.
32. Dokter WH, Dijkstra AJ, Koopmans SB, Mulder AB, Stulp BK, Halie MR, Keck W, Vellenga E. G(Anh)MTetra, a natural bacterial cell wall breakdown product, induces interleukin-1 beta and interleukin-6 expression in human cytokine expression. J Biol Chem 1994;269(6):4201-4206.
33. Yuan Q, Zhao F, Chung SW, Fan P, Sultzer BM, Kan YW, Wong PM. Dominant negative down-regulation of endotoxin-induced tumor necrosis factor alpha production by Lps(d)/Ran. Proc Natl Acad Sci USA 2000;97(6):2852-2857.
34. Lien E, Means TK, Heine H, Yoshimura A, Kusumoto S, Fukase K, Fenton MJ, Oikawa M, Qureshi N, Monks B, Finberg RW, Ingalls RR, Golenbock DT. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J Clin Invest 2000;105(4):497-504.
35. Bave U, Vallin H, Alm GV, Ronnblom L. Activation of natural interferon-alpha producing cells by apoptotic U937 cells combined with lupus IgG and its regulation by cytokines. J Autoimmun 2001;17(1):71-80.
36. Gingras MC, Lapillonne H, Margolin JF. TREM-1, MDL-1, and DAP12 expression is associated with a mature stage of myeloid development. Mol Immunol 2002;38(11):817-824.
37. Jiang Q, Akashi S, Miyake K, Petty HR. Lipopolysaccharide induces physical proximity between CD14 and toll- like receptor 4 (TLR4) prior to nuclear translocation of NF-kappa B. J Immunol 2000;165(7):3541-3544.
38. Bouchon A, Facchetti F, Weigand MA, Colonna M. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 2001;410(6832):1103-1107.
39. Horng T, Medzhitov R. Drosophila MyD88 is an adapter in the Toll signaling pathway. Proc Natl Acad Sci USA 2001:98(22):12654-12658.
40. Akira S, Hoshino K, Kaisho T. The role of Toll-like receptors and MyD88 in innate immune responses. J Endotoxin Res 2000;6(5):383-387.
41. Aliprantis AO, Yang RB, Weiss DS, Godowski P, Zychlinsky A. The apoptotic signaling pathway activated by Toll-like receptor-2. EMBO J 2000;19(13):3325-3336.
42. Baeuerle PA. Pro-inflammatory signaling: last pieces in the NF-kappaB puzzle? Curr Biol 1998;8(1):R19-R22.
43. Caamano J, Hunter CA. NF-kappaB family of transcription factors: central regulators of innate and adaptive immune functions. Clin Microbiol Rev 2002;15(3):414-429.
44. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002;3(3):221-7.
45. Gilmore TD. The Rel/NF-kappaB signal transduction pathway: introduction. Oncogene 1999;18(49):6842-6844.
46. Chen FE, Ghosh G. Regulation of DNA binding by Rel/NF-kappaB transcription factors: structural views. Oncogene 1999;18(49):6845-6852.
47. Mercurio F, Manning AM. Multiple signals converging on NF-kappaB. Curr Opin Cell Biol 1999;11(2):226-232.
48. Lavon I, Goldberg I, Amit S, Landsman L, Jung S, Tsuberi BZ, Barshack I, Kopolovic J, Galun E, Bujard H, Ben-Neriah Y. High susceptibility to bacterial infection, but no liver dysfunction, in mice compromised for hepatocyte NF-kappaB activation. Nat Med 2000;6(5):573-577.
49. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 2001;107(2):135-142.
50. Baldwin AS Jr. Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest 2001;107(1):3-6.
51. Liu SF, Ye X, Malik AB. Inhibition of NF-kappaB activation by pyrrolidine dithiocarbamate prevents In vivo expression of proinflammatory genes. Circulation 1999;100(12):1330-1337.
52. Bohuslav J, Kavchenko VV, Parry GC, Erlich JH, Gerondakis S, Mackman N, Ulevitch RJ. Regulation of an essential innate immune response by the p50 subunit of NF-kappaB. J Clin Invest 1998;102(9):1645-1652.
53. Oliver FJ, Menissier-de Murcia J, Nacci C, Decker P, Andriantsitohaina R, Muller S, de la Rubia G, Stoclet JC, de Murcia G. Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADP-ribose) polymerase-1 deficient mice. EMBO J 1999;18(16):4446-4454.
54. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest 2001;107(1):7-11.
55. Nathan CF. Neutrophil activation on biological surfaces. Massive secretion of hydrogen peroxide in response to products of macrophages and lymphocytes. J Clin Invest 1987;80(6):1550-1560.
56. Beutler B, Mahoney J, Le Trang N, Pekala P, Cerami A. Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med 1985;161(5):984-995.
57. Beutler B, Cerami A. The biology of cachectin/TNF - a primary mediator of the host response. Annu Rev Immunol 1989;7:625-655.
58. Jue DM, Sherry B, Luedke C, Manogue KR, Cerami A. Processing of newly synthesized cachectin/tumor necrosis factor in endotoxin-stimulated macrophages. Biochemistry 1990;29(36):8371-8377.
59. Tosato G, Seamon KB, Goldman ND, Sehgal PB, May LT, Washington GC, Jones KD, Pike SE. Monocyte-derived human B-cell growth factor identified as interferon- beta 2 (BSF-2, IL-6). Science 1988;239(4839):502-504.
60. Assenmacher M, Lohning M, Scheffold A, Manz RA, Schmitz J, Radbruch A. Sequential production of IL-2, IFN-gamma and IL-10 by individual staphylococcal enterotoxin B-activated T helper lymphocytes. Eur J Immunol 1998;28(5):1534- 1543.
61. Aderem AA, Rosen A, Barker KA. Modulation of prostaglandin and leukotriene biosynthesis. Curr Opin Immunol 1988;1(1):56-62.
62. Fernando LP, Fernando AN, Ferlito M, Halushka PV, Cook JA. Suppression of Cox-2 and TNF-alpha mRNA in endotoxin tolerance: effect of cycloheximide, antinomycin D, and okadaic acid. Shock 2000;14(2):128-133.
63. Seki E, Tsutsui H, Tsuji NM, Hayashi N, Adachi K, Nakano H, Futatsugi-Yumikura S, Takeuchi O, Hoshino K, Akira S, Fujimoto J, Nakanishi K. Critical roles of myeloid differentiation factor 88-dependent proinflammatory cytokine release in early phase clearance of Listeria monocytogenes in mice. J Immunol 2002;169(7):3863-3868.
64. Ayala A, Chaudry IH. Platelet activating factor and its role in trauma, shock, and sepsis. New Horiz 1996;4(2):265-275.
65. Lopez-Aguirre Y, Paramo JA. Endothelial cell and hemostatic activation in relation to cytokines in patients with sepsis. Thromb Res 1999;94(2):95-101.
66. Maruyama I. Biology of endothelium. Lupus 1998;7(Suppl 2):S41-S43.
67. Huang K, Fishwild DM, Wu HM, Dedrick RL. Lipopolysaccharide-induced E-selectin expression requires continuous presence of LPS and is inhibited by bactericidal/permeability-increasing protein. Inflammation 1995;19(3):389-404.
68. Hauser IA, Johnson DR, Madri JA. Differential induction of VCAM-1 on human iliac venous and arterial endothelial cells and its role in adhesion. J Immunol 1993;151(10):5172-5185.
69. Spiecker M, Darius H, Liao JK. A functional role of I kappa B-epsilon in endothelial cell activation. J Immunol 2000;164(6):3316-3322.
70. Scalia R, Armstead VE, Minchenko AG, Lefer AM. Essential role of P-selectin in the initiation of the inflammatory response induced by hemorrhage and reinfusion. J Exp Med 1999;189(6):931-938.
71. Pearson PJ, Lin PJ, Schaff HV. Production of endothelium-derived contracting factor is enhanced after coronary reperfusion. Ann Thorac Surg 1991;51(5):788-793.
72. Graeve L, Baumann M, Heinrich PC. Interleukin-6 in autoimmune disease. Role of IL-6 in physiology and pathology of the immune defense. Clin Invest 1993;71(8):664-671.
73. Gill EA, Imaizumi T, Carveth H, Topham MK, Tarbet EB, McIntyre TM, Prescott SM, Zimmerman GA. Bacterial lipopolysaccharide induces endothelial cells to synthesize a degranulating factor for neutrophils. FASEB J 1998;12(9):673-684.
74. Derfalvi B, Igaz P, Fulop KA, Szalai C, Falus A. Interleukin-6-induced production of type II acute phase proteins and expression of junB gene are downregulated by human recombinant growth hormone in vitro. Cell Biol Int 2000;24(2):109-114.
75. Ray A, Hannink M, Ray BK. Concerted participation of NF-kappa B and C/EBP heteromer in lipopolysaccharide induction of serum amyloid A gene expression in liver. J Biol Chem 1995;270(13):7365-7374.
76. Gibson FC 3rd, Onderdonk AB, Kasper DL, Tzianabos AO. Cellular mechanism of intraabdominal abscess formation by Bacteroides fragilis. J Immunol 1998;160(10):5000-5006.
77. Ferlito M, Romanenko OG, Ashton S, Squadrito F, Halushka PV, Cook JA. Effect of cross-tolerance between endotoxin and TNF-alpha or IL-1beta on cellular signaling and mediator production. J Leukoc Biol 2001;70(5):821-829.
78. Bonizzi G, Piette J, Merville MP, Bours V. Distinct signal transduction pathways mediate nuclear factor-kappaB induction by IL-1beta in epithelial and lymphoid cells. J Immunol 1997;159(11):5264-5272.
79. Glynne PA, Evans TJ. Inflammatory cytokines induce apoptotic and necrotic cell shedding from human proximal tubular epithelial cell monolayers. Kidney Int 1999;55(6):2573-2597.
80. Dinarello CA, Cannon JG, Wolff SM, Bernheim HA, Beutler B, Cerami A, Figari IS, Palladino MA Jr, O'Connor JV. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 1986;163(6):1433-1450.
81. Raivich G, Bohatschek M, Werner A, Jones LL, Galiano M, Kloss CU, Zhu XZ, Pfeffer K, Liu ZQ. Lymphocyte infiltration in the injured brain: Role of proinflammatory cytokines. J Neurosci Res 2003;72(6):726-733.
82. Espinosa E, Bermúdez-Rattoni F. Behavior-immunity relationship: the role of cytokines. Rev Invest Clin 2001;53(3):240-253.
83. Dantzer R, Konsman JP, Bluthe RM, Kelley KW. Neural and humoral pathways of communication from the immune system to the brain: parallel or convergent? Auton Neurosci 2000;85(1-3):60-65.
84. Zentella A, Manogue K, Cerami A. The role of cachectin/TNF and other cytokines in sepsis. Prog Clin Biol Res 1991;367:9-24.
85. Blatteis CM. The afferent signalling of fever. J Physiol 2000;526Pt 3:470.
86. Wang ZQ, Bapat AS, Rayanade RJ, Dagtas AS, Hoffmann MK. Interleukin-10 induces macrophage apoptosis and expression of CD16 (FcgammaRIII) whose engagement blocks the cell death programme and facilitates differentiation. Immunology 2001;102(3):331-337.
87. Smith WB, Noack L, Khew-Goodall Y, Isenmann S, Vadas MA, Gamble JR. Transforming growth factor-beta1 inhibits the production of IL-8 and the transmigration of neutrophils through activated endothelium. J Immunol 1996;157(1):360-368.
88. Celada A, Gray PW, Rinderknecht E, Schreiber RD. Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity. J Exp Med 1984;160(1):55-74.
89. Hume DA, Underhill DM, Sweet MJ, Ozinsky AO, Liew FY, Aderem A. Macrophages exposed continuously to lipopolysaccharide and other agonists that act via toll-like receptors exhibit a sustained and additive activation state. BMC Immunol 2001;2(1):11.
90. Cummings CJ, Martin TR, Frevert CW, Quan JM, Wong VA, Mongovin SM, Hagen TR, Steinberg KP, Goodman RB. Expression and function of the chemokine receptors CXCR1 and CXCR2 in sepsis. J Immunol 1999;162(4):2341-2346.
91. Mantovani A. Chemokines. Introduction and overview. Chem Immunol 1999;72:1-6.
92. Chandrasekar B, Mummidi S, Perla RP, Bysani S, Dulin NO, Liu F, Melby PC. Fractalkine (CX3CL1) stimulated by NF-kappaB-dependent inflammatory signals induces aortic smooth muscle cells proliferation through an autocrine pathway. Biochem J 2003;373(Pt 2):547-558.
93. Dejana E, Corada M, Lampugnani MG. Endothelial cell-to-cell junctions. FASEB J 1995;9(10):910-918.
94. Dejana E, Del Maschio A. Molecular organization and functional regulation of cell to cell junctions in the endothelium. Thromb Haemost 1995;74(1):309-312.
95. Worrall NK, Chang K, LeJeune WS, Misko TP, Sullivan PM, Ferguson TB Jr, Williamson JR. TNF-alpha causes reversible in vivo systemic vascular barrier dysfunction via NO-dependent and -independent mechanisms. Am J Physiol 1997;273(6 Pt 2):H2565-H2574.
96. Anrather D, Millan MT, Palmetshofer A, Robson SC, Geczy C, Ritchie AJ, Bach FH, Ewenstein BM. Thrombin activates nuclear factor-kappaB and potentiates endothelial cell activation by TNF. J Immunol 1997;159(11):5620-5628.
97. Carraway MS, Welty-Wolf KE, Miller DL, Ortel TL, Idell S, Ghio AJ, Petersen LC, Piantadosi CA. Blockade of tissue factor: treatment for organ injury in established sepsis. Am J Respir Crit Care Med 2003;167(9):1200-1209.
98. Jaffe EA. Cell biology of endothelial cells. Hum Pathol 1987;18(3):234-239.
99. Drouet L. Venous thromboembolic pathology. Arch Mal Coeur Vaiss 2001;94(11 Suppl):1318-1326.
100. De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr, Shin WS, Liao J. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995;96(1):60-68.
101. Johns DG, Webb RC. TNF-alpha-induced endothelium-independent vasodilation: A role for phospholipase A2-dependent ceramide signaling. Am J Physiol 1998;275(5 Pt 2):H1592-H1598.
102. Colwell J. Pathogenesis of vascular disease. Diabetes Obes Metab 2000;2Suppl 2:S19-S24.
103. Marrero MB, Venema VJ, Ju H, He H, Liang H, Caldwell RB, Venema RC. Endothelial nitric oxide synthase interactions with G-protein-coupled receptors. Biochem J 1999;343Pt 2:335-340.
104. Li H, Forstermann U. Nitric oxide in the pathogenesis of vascular disease. J Pathol 2000;190(3):244-254.
105. Zhou M, Wang P, Chaudry IH. Endothelial nitric oxide synthase is downregulated during hyperdynamic sepsis. Biochim Biophys Acta 1997;1335(1-2):182-190.
106. Parratt JR. Nitric oxide in sepsis and endotoxaemia. J Antimicrob Chemother 1998;41(Suppl A):31-39.
107. Galley HF, Nelson SJ, Dhillon J, Dubbels AM, Webster NR. Effect of the nitric oxide inhibitor, L-N(G)-monomethylarginine, on accumulation of interleukin-6 and interleukin-8, and nuclear factor-kappaB activity in a human endothelial cell line. Crit Care Med 1999;27(5):908-912.
108. Stoclet JC, Martinez MC, Ohlmann P, Chasserot S, Schott C, Kleschyov AL, Schneider F, Andriantsitohaina R. Induction of nitric oxide synthase and dual effects of nitric oxide and cyclooxygenase products in regulation of arterial contraction in human septic shock. Circulation 1999;100(2):107-112.
109. Blanco JC, Contursi C, Salkowski CA, DeWitt DL, Ozato K, Vogel SN. Interferon regulatory factor (IRF)-1 and IRF-2 regulate interferon gamma-dependent cyclooxygenase 2 expression. J Exp Med 2000;191(12):2131-2144.
110. Tracey KJ, Morgello S, Koplin B, Fahey TJ 3rd, Fox J, Aledo A, Manogue KR, Cerami A. Metabolic effects of cachectin/tumor necrosis factor are modified by site of production. Cachectin/tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominantly acute anorexia. J Clin Invest 1990;86(6):2014-2024.
111. Baker SJ, Reddy EP. Modulation of life and death by the TNF receptor superfamily. Oncogene 1998;17(25):3261-3270.
112. Kumar A, Thota V, Dee L, Olson J, Uretz E, Parrillo JE. Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med 1996;183(3):949-958.
113. Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol 1998;274(3 Pt 2):R577-R595.
114. Tracey KJ, Cerami A. Metabolic responses to cachectin/TNF. A brief review. Ann NY Acad Sci 1990;587:325-331.
115. Calvin JW. Thoracoscopy and intrathoracic extrapleural lipoma. Chest 1977;71(1):121.
116. Maitra SR, Wojnar MM, Lang CH. Alterations in tissue glucose uptake during the hyperglycemic and hypoglycemic phases of sepsis. Shock 2000;13(5):379-385.
117. McCallum RE. Hepatocyte-Kupffer cell interactions in the inhibition of hepatic gluconeogenesis by bacterial endotoxin. Prog Clin Biol Res 1981;62:99-113.
118. Zentella A, Manogue K, Cerami A. Cachectin/TNF-mediated lactate production in cultured myocytes is linked to activation of a futile substrate cycle. Cytokine 1993;5(5):436-447.
119. Gellerich FN, Trumbeckaite S, Hertel K, Zierz S, Muller-Werdan U, Werdan K, Redl H, Schlag G. Impaired energy metabolism in hearts of septic baboons: diminished activities of Complex I and Complex II of the mitochondrial respiratory chain. Shock 1999;11(5):336-341.
120. Vary TC, Hazen SA, Maish G, Cooney RN. TNF binding protein prevents hyperlactatemia and inactivation of PDH complex in skeletal muscle during sepsis. J Surg Res 1998;80(1):44-51.
121. Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J, Williams R. The systemic inflammatory response syndrome in acute liver failure. Hepatology 2000;32(4 Pt 1):734-739.
122. Oertli B, Beck-Schimmer B, Fan X, Wuthrich RP. Mechanisms of hyaluronan-induced up-regulation of ICAM-1 and VCAM-1 expression by murine kidney tubular epithelial cells: hyaluronan triggers cell adhesion molecule expression through a mechanism involving activation of nuclear factor-kappa B and activating protein-1. J Immunol 1998;161(7):3431-3437.
123. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985;229(4716):869-871.
124. Opal SM CJ. Clinical gram-positive sepsis: does it fundamentally differ from gram-negative bacterial sepsis? Crit Care Med 1999;27(8):1608-1616.
125. Chehab MS. Can we reduce mortality in sepsis? Saudi Med J 2004;25(3):277-284.
126. Dhainaut JF YS, Claessens YE. Protein C/activated protein C pathway: overview of clinical trial results in severe sepsis. Crit Care Med 2004;32(5 Suppl):S194-S201.
127. Murata A. Granulocyte colony-stimulating factor as the expecting sword for the treatment of severe sepsis. Curr Pharm Des 2003;9(14):1115-1120.
128. Williams DL, Ha T, Li C, Kalbfleisch JH, Laffan JJ, Ferguson DA. Inhibiting early activation of tissue nuclear factor-kappa B and nuclear factor interleukin 6 with (1->3)-beta-D-glucan increases long-term survival in polymicrobial sepsis. Surgery 1999;126(1):54-65.
129. Caille VBP, Grimaldi D, Vieillard-Baro A. Physiopathology of severe sepsis. Presse Med 2004;33(4):256-261.
130. Janssens UGJ. Shock: What are the basics? Internist (Berl). 2004;45(3):258-266.
131. Cross AS, Opal SM. A new paradigm for the treatment of sepsis: is it time to consider combination therapy? Ann Intern Med 2003;138(6):502-505.
132. Opal SM, Cross AS. Clinical trials for severe sepsis. Past failures, and future hopes. Infect Dis Clin North Am 1999;13(2):285-297,vii.